JP2022514618A - Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド - Google Patents

Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド Download PDF

Info

Publication number
JP2022514618A
JP2022514618A JP2021535745A JP2021535745A JP2022514618A JP 2022514618 A JP2022514618 A JP 2022514618A JP 2021535745 A JP2021535745 A JP 2021535745A JP 2021535745 A JP2021535745 A JP 2021535745A JP 2022514618 A JP2022514618 A JP 2022514618A
Authority
JP
Japan
Prior art keywords
seq
referred
hereinafter referred
sdk
sar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535745A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020128526A5 (enExample
Inventor
シェン リューホン
クック ジェームズ
マクドネル ケビン
マッド ジェマ
ヴァン リーツチョーテン カテリーヌ
ウパディヤヤ プニット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1820956.9A external-priority patent/GB201820956D0/en
Priority claimed from GBGB1904621.8A external-priority patent/GB201904621D0/en
Priority claimed from GBGB1905631.6A external-priority patent/GB201905631D0/en
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of JP2022514618A publication Critical patent/JP2022514618A/ja
Publication of JPWO2020128526A5 publication Critical patent/JPWO2020128526A5/ja
Priority to JP2024174010A priority Critical patent/JP2025020121A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021535745A 2018-12-21 2019-12-23 Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド Pending JP2022514618A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024174010A JP2025020121A (ja) 2018-12-21 2024-10-03 Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1820956.9 2018-12-21
GBGB1820956.9A GB201820956D0 (en) 2018-12-21 2018-12-21 Bicyclic peptide ligands specific for pd-l1
GB1904621.8 2019-04-02
GBGB1904621.8A GB201904621D0 (en) 2019-04-02 2019-04-02 Bicyclic peptide ligands specific for PD-L1
GB1905631.6 2019-04-23
GBGB1905631.6A GB201905631D0 (en) 2019-04-23 2019-04-23 Bicyclic peptide ligands specific for pd-l1
US201962910113P 2019-10-03 2019-10-03
US62/910,113 2019-10-03
PCT/GB2019/053679 WO2020128526A1 (en) 2018-12-21 2019-12-23 Bicyclic peptide ligands specific for pd-l1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024174010A Division JP2025020121A (ja) 2018-12-21 2024-10-03 Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド

Publications (2)

Publication Number Publication Date
JP2022514618A true JP2022514618A (ja) 2022-02-14
JPWO2020128526A5 JPWO2020128526A5 (enExample) 2022-12-28

Family

ID=71100278

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535745A Pending JP2022514618A (ja) 2018-12-21 2019-12-23 Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
JP2024174010A Pending JP2025020121A (ja) 2018-12-21 2024-10-03 Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024174010A Pending JP2025020121A (ja) 2018-12-21 2024-10-03 Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド

Country Status (5)

Country Link
US (1) US12492224B2 (enExample)
EP (1) EP3897849A1 (enExample)
JP (2) JP2022514618A (enExample)
CN (1) CN113474045A (enExample)
WO (1) WO2020128526A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN119192401A (zh) 2019-10-03 2024-12-27 拜斯科技术开发有限公司 异串联双环肽复合物
CN111961117B (zh) * 2020-08-19 2022-03-11 中山大学 一种环肽化合物及其应用
AR126029A1 (es) * 2020-11-13 2023-09-06 Bicycletx Ltd LIGANDOS DE PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EL RECEPTOR DE TRANSFERRINA 1 (TfR1)
EP4251190A4 (en) * 2020-11-30 2024-10-23 Fred Hutchinson Cancer Center PD-L1-BINDING PEPTIDES, PEPTIDE COMPLEXES AND METHODS OF USE THEREOF
AU2022206394A1 (en) * 2021-01-08 2023-08-24 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
AU2022206577A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
MX2024002098A (es) * 2021-08-17 2024-03-05 Medshine Discovery Inc Conjugado farmaco-polipeptido con estructura innovadora y su aplicacion.
WO2024261490A1 (en) 2023-06-23 2024-12-26 Bicycletx Limited Bicyclic peptide ligands specific for nk cells

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514803A (ja) * 2008-02-05 2011-05-12 メディカル リサーチ カウンシル 方法及び組成物
JP2013507926A (ja) * 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
JP2013518558A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 構造化されたペプチドプロセシング
JP2013518807A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
JP2016527180A (ja) * 2013-03-15 2016-09-08 バイサイクル・セラピューティクス・リミテッド ポリペプチドの修飾
US20170165334A1 (en) * 2015-12-11 2017-06-15 Tianxin Wang Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
WO2017191460A1 (en) * 2016-05-04 2017-11-09 Bicycle Therapeutics Limited Bicyclic peptide-toxin conjugates specific for mt1-mmp
WO2018133873A1 (zh) * 2017-01-23 2018-07-26 苏州康宁杰瑞生物科技有限公司 Pd-l1结合多肽或化合物
JP2018521960A (ja) * 2015-04-28 2018-08-09 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 酵素で活性化された第ＸＩＩ因子（ＦＸＩＩａ）の新規阻害剤
WO2018210927A2 (en) * 2017-05-16 2018-11-22 Fastbase Solutions Ltd Kits, methods and their uses for detecting cell-cell interactions in a sample kits

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642514A (en) 1946-08-10 1953-06-16 American Cyanamid Co Ion exchange process with magnetic ion exchange resins
GB1239978A (en) 1968-07-15 1971-07-21 Permutt Company Ltd Ion-exchange processes
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
EP0941120A4 (en) 1996-11-05 2004-08-18 Bristol Myers Squibb Co BRANCHED PEPTIDLINKERS
US6410275B1 (en) 1997-05-02 2002-06-25 Biomerieux, Inc. Disposable test devices for performing nucleic acid amplification reactions
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
CA2345376C (en) 1998-09-24 2010-03-16 Advanced Research And Technology Institute, Inc. Water-soluble luminescent quantum dots and bioconjugates thereof
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
CN1195755C (zh) 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HUE026218T2 (en) 2002-02-21 2016-05-30 Inst Virology MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
DE60325740D1 (de) 2002-08-14 2009-02-26 Silence Therapeutics Ag Verwendung von protein-kinase-n-beta
JP2006514104A (ja) 2002-12-12 2006-04-27 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． グリコーゲンシンターゼキナーゼ−３阻害剤
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
SI1644363T1 (sl) 2003-05-30 2012-07-31 Gemin X Pharmaceuticals Canada Inc Triheterociklične spojine sestavki in postopki za zdravljenje raka
EP2371835A1 (en) 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
US7151047B2 (en) 2004-04-28 2006-12-19 Warren Chan Stable, water-soluble quantum dot, method of preparation and conjugates thereof
ES2873875T3 (es) 2004-05-13 2021-11-04 Icos Corp Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
NZ555947A (en) 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
PL1844337T3 (pl) 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
WO2006101187A1 (en) 2005-03-22 2006-09-28 Rohto Pharmaceutical Co., Ltd. Peptides that increase collagen or hyaluronic acid production
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CA2621502A1 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
CN101282948A (zh) 2005-10-07 2008-10-08 埃克塞里艾克西斯公司 N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
MX2009002775A (es) 2006-09-15 2009-06-17 Siemens Medical Solutions Derivados de ciclopeptido de quimica click como agentes de formacion de imagen para integrinas.
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
CN101232326B (zh) 2007-01-22 2012-01-11 中兴通讯股份有限公司 用于无源光网络系统的动态带宽分配装置及其实现方法
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
EP2155177A2 (en) 2007-04-30 2010-02-24 Intezyne Technologies Incorporated Modification of biological targeting groups for the treatment of cancer
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CN101918844A (zh) 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
CN101497878B (zh) 2008-01-30 2012-11-07 房学迅 特异性高效亲和膜ⅰ型基质金属蛋白酶(mt1-mmp)的多肽、蛋白及其应用
WO2009097397A2 (en) 2008-01-30 2009-08-06 Dyax Corp. Metalloproteinase binding proteins
KR101595138B1 (ko) 2008-02-27 2016-02-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 괴사종양의 광역학요법 및 영상용 알지디(박테리오)클로로필 컨쥬게이트
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
FR2932189A1 (fr) 2008-06-10 2009-12-11 Commissariat Energie Atomique Biopuces pour la detection de l'activite enzymatique d'une enzyme protease
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8834926B2 (en) 2008-08-08 2014-09-16 University Of Delaware Macromolecular diffusion and release from self-assembled β-hairpin peptide hydrogels
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
CA2769444A1 (en) 2009-05-19 2010-11-25 Aic Blab Company Composite current collector and methods therefor
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
RS58693B1 (sr) 2009-12-10 2019-06-28 Hoffmann La Roche Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena
WO2011079015A1 (en) 2009-12-21 2011-06-30 The Regents Of The University Of California Rgd-containing cyclic peptides
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
BR112012020372A8 (pt) 2010-03-05 2018-01-02 Hoffmann La Roche anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante
KR20200044999A (ko) 2010-05-04 2020-04-29 파이브 프라임 테라퓨틱스, 인크. Ｃｓｆ1ｒ에 결합하는 항체들
PH12020550156A1 (en) 2010-09-09 2024-01-15 Pfizer 4-1bb binding molecules
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130072598A1 (en) 2011-03-18 2013-03-21 Board Of Regents Of The University Of Nebraska Thermoplastics from Distillers Dried Grains and Feathers
NO2694640T3 (enExample) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CN103906865B (zh) 2011-10-07 2017-12-08 拜斯科医疗有限公司 结构化多肽特异性的调控
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
BR112014018961A8 (pt) 2012-02-06 2017-07-11 Genentech Inc Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
BR112014028013A2 (pt) 2012-05-11 2018-02-27 Five Prime Therapeutics Inc métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
JP6321658B2 (ja) 2012-09-24 2018-05-09 メディミューン リミテッド アミノ酸誘導体
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
CN105051067B (zh) 2013-03-12 2020-04-17 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
WO2014142237A1 (ja) 2013-03-15 2014-09-18 日本ゼオン株式会社 中空重合体粒子の水性分散液およびその製造方法
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
CA2916725A1 (en) 2013-07-22 2015-01-29 Kineta One, Llc Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
CN118146306A (zh) 2013-09-25 2024-06-07 西托姆克斯治疗公司 基质金属蛋白酶底物和其它可切割部分及其使用方法
WO2015063465A2 (en) 2013-10-28 2015-05-07 Bicycle Therapeutics Limited Novel polypeptides
KR102408261B1 (ko) 2014-02-03 2022-06-10 비타이 파마슈티컬즈, 엘엘씨 Ror-감마의 디하이드로피롤로피리딘 저해제
AU2015255883A1 (en) 2014-05-08 2016-10-27 Novodiax, Inc. Direct immunohistochemistry assay
CN113861268B (zh) 2014-05-21 2025-04-01 恩特拉达治疗学股份有限公司 细胞穿透肽及其制备和使用方法
AU2015273934B2 (en) * 2014-06-10 2020-08-20 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
WO2016050361A1 (en) 2014-09-30 2016-04-07 Polyphor Ag Beta-hairpin peptidomimetics
AU2015335725B2 (en) 2014-10-24 2021-06-03 Research Corporation Technologies, Inc. Small antibody-like polypeptides that bind to EphA2 receptor
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
CN107406463A (zh) 2014-12-04 2017-11-28 细胞基因公司 生物分子共轭物
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
EP3287027B1 (en) 2015-04-22 2021-07-28 Mitsui Chemicals, Inc. Clothing provided with joint supporter portion, and knee supporter
WO2016171242A1 (ja) 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
CN107849116A (zh) 2015-05-06 2018-03-27 詹森生物科技公司 前列腺特异性膜抗原结合iii型纤连蛋白结构域
HRP20231392T1 (hr) * 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
US9963495B2 (en) 2015-10-27 2018-05-08 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
GB201600911D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
US10765625B2 (en) 2016-03-15 2020-09-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
EP3429630A1 (en) 2016-03-16 2019-01-23 Merrimack Pharmaceuticals, Inc. Nanoliposomal targeting of ephrin receptor a2 (epha2) and related diagnosticss
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
MY197235A (en) 2016-04-20 2023-06-07 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
WO2017182672A1 (en) 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
BR112018074453A2 (pt) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
WO2018096365A1 (en) 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
EP3559019A1 (en) 2016-12-23 2019-10-30 BicycleTX Limited Peptide ligands for binding to mt1-mmp
WO2018127699A1 (en) 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
WO2018222987A1 (en) 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
EP3668887A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
US20200283482A1 (en) 2017-08-14 2020-09-10 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
WO2019136442A1 (en) 2018-01-08 2019-07-11 Kleo Pharmaceuticals, Inc. Cd16a binding agents and uses thereof
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
KR20200139236A (ko) 2018-04-04 2020-12-11 바이사이클티엑스 리미티드 헤테로탠덤 비사이클릭 펩티드 복합체
CN112384534A (zh) 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
GB201810325D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
EP3870597A1 (en) 2018-10-23 2021-09-01 BicycleTx Limited Bicyclic peptide ligands and uses thereof
CA3116504A1 (en) 2018-10-30 2020-05-07 Bicyclerd Limited Bt1718 for use in treating cancer
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
JP2022513806A (ja) 2018-12-13 2022-02-09 バイスクルテクス・リミテッド Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020131697A2 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
US10882987B2 (en) 2019-01-09 2021-01-05 Nova Chemicals (International) S.A. Ethylene interpolymer products having intermediate branching
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
CA3135569A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TWI869398B (zh) 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4013501A1 (en) 2019-08-13 2022-06-22 BicycleTX Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
CN119192401A (zh) 2019-10-03 2024-12-27 拜斯科技术开发有限公司 异串联双环肽复合物
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
US20220387611A1 (en) 2019-10-16 2022-12-08 Bicyclerd Limited Methods for treating cancer
US20230025916A1 (en) 2019-11-27 2023-01-26 Bicycle TX Limited BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF
IT202000001231A1 (it) 2020-01-22 2021-07-22 Celery S R L Nuovi ceppi di batteri lattici, composizione alimentare che li comprende, preparazione di tale composizione
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
KR20230037502A (ko) 2020-05-20 2023-03-16 바이사이클티엑스 리미티드 넥틴-4에 특이적인 바이사이클릭 펩티드 리간드 및 이의 용도
AU2021289095A1 (en) 2020-06-12 2023-01-05 Bicycletx Limited Treatment of diseases characterized by overexpression of Erythropoietin-producing hepatocellular receptor A2 (EphA2)
WO2022029420A1 (en) 2020-08-03 2022-02-10 Bicycletx Limited Peptide-based linkers
US20240240255A1 (en) 2020-08-17 2024-07-18 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
AU2022206577A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Heterotandem bicyclic peptide complexes
AU2022206394A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
WO2022148969A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
IL310795A (en) 2021-09-03 2024-04-01 Bicycletx Ltd Synthesis of bicycle toxin conjugates, and intermediates thereof
JP2024543505A (ja) 2021-11-16 2024-11-21 バイスクルテクス・リミテッド 癌の治療方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514803A (ja) * 2008-02-05 2011-05-12 メディカル リサーチ カウンシル 方法及び組成物
JP2013507926A (ja) * 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
JP2013518558A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 構造化されたペプチドプロセシング
JP2013518807A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
JP2016527180A (ja) * 2013-03-15 2016-09-08 バイサイクル・セラピューティクス・リミテッド ポリペプチドの修飾
JP2018521960A (ja) * 2015-04-28 2018-08-09 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 酵素で活性化された第ＸＩＩ因子（ＦＸＩＩａ）の新規阻害剤
US20170165334A1 (en) * 2015-12-11 2017-06-15 Tianxin Wang Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
WO2017191460A1 (en) * 2016-05-04 2017-11-09 Bicycle Therapeutics Limited Bicyclic peptide-toxin conjugates specific for mt1-mmp
WO2018133873A1 (zh) * 2017-01-23 2018-07-26 苏州康宁杰瑞生物科技有限公司 Pd-l1结合多肽或化合物
WO2018210927A2 (en) * 2017-05-16 2018-11-22 Fastbase Solutions Ltd Kits, methods and their uses for detecting cell-cell interactions in a sample kits

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HELMUS VAN DE LANGEMHEEN ET AL., CHEMBIOCHEM, vol. 18, JPN6023051135, 2017, pages 387 - 395, ISSN: 0005221804 *
SHABNAM SHAABANI ET AL., EXPERT OPIN THER PAT., vol. 28, no. 9, JPN6023051134, September 2018 (2018-09-01), pages 665 - 678, ISSN: 0005221802 *
SHIYU CHEN ET AL., CHEMBIOCHEM, vol. 13, JPN6023051136, 2012, pages 1032 - 1038, ISSN: 0005221805 *
SHIYU CHEN; ET AL: "PEPTIDE LIGANDS STABILIZED BY SMALL MOLECULES", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. VOL:53, NR:6, JPN5022003762, 3 February 2014 (2014-02-03), DE, pages 1602 - 1606, ISSN: 0005221803 *

Also Published As

Publication number Publication date
CN113474045A (zh) 2021-10-01
JP2025020121A (ja) 2025-02-12
US12492224B2 (en) 2025-12-09
WO2020128526A1 (en) 2020-06-25
US20220306689A9 (en) 2022-09-29
EP3897849A1 (en) 2021-10-27
US20210101932A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
JP2022514618A (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
JP7579840B2 (ja) ヘテロタンデム二環式ペプチド複合体
CN111741771B (zh) 特异于epha2的双环肽配体
JP2022514687A (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
CN111183147B (zh) Cd137特异性的双环肽配体
JP2022514255A (ja) Ｐｓｍａに特異的な二環式ペプチドリガンド
JP2022552839A (ja) 二環式ペプチドリガンド薬物コンジュゲート
JP2022518695A (ja) Ｃａｉｘに特異的な二環式ペプチドリガンド
JP2022518210A (ja) インテグリンαｖβ３に特異的な二環式ペプチドリガンド
CN113543813B (zh) Cd38特异性的双环肽配体
JP2022512478A (ja) Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
RS61853B1 (sr) Biciklični peptidni ligandi specifični za mt1-mmp
JP2022513806A (ja) Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
JP2022517442A (ja) Ｃａｉｘに特異的な二環式ペプチドリガンド
JP2022517698A (ja) インテグリンαｖβ３に特異的な二環式ペプチドリガンド
JP2022513223A (ja) Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
CN112585157A (zh) 用于结合整联蛋白αvβ3的肽配体
JP2022517399A (ja) Ｃｄ３８に特異的な二環式ペプチドリガンド
JP2022515720A (ja) Ｉｌ－１７に特異的な二環式ペプチドリガンド
JP2022515721A (ja) ＦＡＰαに特異的な二環式ペプチドリガンド
JP2023506083A (ja) Ｉｌ－１７に特異的な二環式ペプチドリガンド
JP2023506874A (ja) Ｉｌ－１７に特異的な二環式ペプチドリガンド
JP2023506270A (ja) Ｉｌ－１７に特異的な二環式ペプチドリガンド
JP2023507134A (ja) Ｉｌ－１７に特異的な二環式ペプチドリガンド
EA046810B1 (ru) Бициклические пептидные лиганды, специфичные к mt1-mmp

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241003

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241025